Treprostinil 0.125 mg TID orally, which will be increased by 0.125 mg TID every 3 to 4 days as tolerated for 12 months

Systemic Sclerosis

Calcinosis

Treprostinil 0.125 mg TID orally, which will be increased by 0.125 mg TID every 3 to 4 days as tolerated

Oral treprostinil

Stanford University School of Medicine

Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis

A Pilot Study to Evaluate the Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis

Number of participants with treatment-related adverse events following

mean rate of change of calcinosis in radiograph following treatment with oral treprostinil as assessed by a novel radiographic scoring system

The Scleroderma Health Assessment Questionnaire (SHAQ) consists of the mean of 8 scores from 8 sections ranging from 0-3 and 6 visual analogue scales ranging from 0-10. The higher the score, the higher the disability.

Cochin Hand Functional Scale is a 18-questions scale, each question ranges from 0 to 5, total score range 0-90. Higher scores indicates higher disability.

The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale. The higher the score the less disability.

Mawdsley Calcinosis Questionnaire is an 18-question survey, each question ranges from 0-10. Higher scores indicates higher disability from calcinosis

The Raynaud Condition Score is a single question questionnaire, ranges from 0-10, where 10 indicates more active Raynaud phenomenon.

patient global assessment of calcinosis severity at 1 year versus baseline

physician global assessment of calcinosis severity at 1 year versus baseline

SSc-PAH associated biomarkers following treatment with treprostinil at 1 year compared to baseline

baseline cortical area and cortical porosity measured by HR-pQCT in SSc patients with calcinosis at baseline

n butyl alcohol/eпилептички напад

Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis

Најкомплетнија база лековитог биља подржана науком